PT3482767T - Terapia de substituição enzimática com escaladas de dose para tratamento de deficência da esfingomielinase ácida - Google Patents

Terapia de substituição enzimática com escaladas de dose para tratamento de deficência da esfingomielinase ácida

Info

Publication number
PT3482767T
PT3482767T PT181993585T PT18199358T PT3482767T PT 3482767 T PT3482767 T PT 3482767T PT 181993585 T PT181993585 T PT 181993585T PT 18199358 T PT18199358 T PT 18199358T PT 3482767 T PT3482767 T PT 3482767T
Authority
PT
Portugal
Prior art keywords
replacement therapy
dose escalation
enzyme replacement
acid sphingomyelinase
treating acid
Prior art date
Application number
PT181993585T
Other languages
English (en)
Original Assignee
Icahn School Med Mount Sinai
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3482767(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Icahn School Med Mount Sinai, Genzyme Corp filed Critical Icahn School Med Mount Sinai
Publication of PT3482767T publication Critical patent/PT3482767T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
PT181993585T 2009-08-28 2010-08-28 Terapia de substituição enzimática com escaladas de dose para tratamento de deficência da esfingomielinase ácida PT3482767T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23811309P 2009-08-28 2009-08-28

Publications (1)

Publication Number Publication Date
PT3482767T true PT3482767T (pt) 2021-12-29

Family

ID=43625265

Family Applications (2)

Application Number Title Priority Date Filing Date
PT181993585T PT3482767T (pt) 2009-08-28 2010-08-28 Terapia de substituição enzimática com escaladas de dose para tratamento de deficência da esfingomielinase ácida
PT10812683T PT2470199T (pt) 2009-08-28 2010-08-28 Terapia de substituição enzimática com escaladas de dose para tratamento de deficência em esfingomielinase ácida

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT10812683T PT2470199T (pt) 2009-08-28 2010-08-28 Terapia de substituição enzimática com escaladas de dose para tratamento de deficência em esfingomielinase ácida

Country Status (26)

Country Link
US (9) US8349319B2 (pt)
EP (3) EP3482767B1 (pt)
JP (7) JP5955219B2 (pt)
KR (5) KR102608546B1 (pt)
CN (3) CN106047835A (pt)
AU (5) AU2010286550B2 (pt)
BR (1) BR112012004377A2 (pt)
CA (1) CA2773133A1 (pt)
CL (1) CL2012000495A1 (pt)
CY (1) CY1122128T1 (pt)
DK (2) DK3482767T3 (pt)
ES (2) ES2738859T3 (pt)
FR (1) FR22C1062I2 (pt)
HR (2) HRP20211992T1 (pt)
HU (3) HUE046598T2 (pt)
IL (3) IL300625A (pt)
LT (2) LT3482767T (pt)
MX (1) MX356873B (pt)
NL (1) NL301211I2 (pt)
PL (2) PL3482767T3 (pt)
PT (2) PT3482767T (pt)
RU (3) RU2731616C2 (pt)
SI (2) SI2470199T1 (pt)
TR (1) TR201911293T4 (pt)
WO (1) WO2011025996A2 (pt)
ZA (2) ZA201201435B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
ES2635726T3 (es) 2007-06-06 2017-10-04 Genzyme Corporation Terapia génica para enfermedades de almacenamiento lisosómico
EP3482767B1 (en) * 2009-08-28 2021-10-06 Icahn School of Medicine at Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US8882701B2 (en) 2009-12-04 2014-11-11 Smiths Medical Asd, Inc. Advanced step therapy delivery for an ambulatory infusion pump and system
US20120034638A1 (en) 2010-05-21 2012-02-09 Michael Ahrens Electrochemical assay for the detection of enzymatically active PSA
PT2685986T (pt) 2011-03-18 2020-03-05 Genzyme Corp Inibidor de glicosilceramida-sintase
LT2753346T (lt) 2011-09-07 2020-08-10 Mount Sinai School Of Medicine Ceramidazė ir ląstelių diferenciacija
EP2780716B1 (en) 2011-11-15 2019-07-31 Centogene AG Method for the diagnosis of niemann-pick disease
ES2897825T3 (es) 2012-06-01 2022-03-02 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
EP2968479B1 (en) 2013-03-14 2019-07-17 Icahn School of Medicine at Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
TR201906195T4 (tr) * 2013-05-14 2019-05-21 Centogene Ag Niemann pıck hastalığının teşhisi için metot.
IL284102B2 (en) * 2013-06-07 2023-04-01 Genzyme Corp A marker for disorders of acid sphingomyelinase and its uses
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病ｃ型を予防または治療するための医薬組成物
US10569016B2 (en) 2015-12-29 2020-02-25 Tandem Diabetes Care, Inc. System and method for switching between closed loop and open loop control of an ambulatory infusion pump
KR20200044064A (ko) 2017-08-24 2020-04-28 사노피 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
UY38238A (es) 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
AU2021311131A1 (en) 2020-07-24 2023-03-23 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
IL74761A0 (en) 1984-04-13 1985-06-30 Hughes Howard Med Inst Human phenylalanine hydroxylase cdna clones,their production and their use in diagnosing classical phenylketonuria
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4863195A (en) * 1987-10-02 1989-09-05 Capozzola Carl A Identification tag
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
EP0865499B1 (en) 1995-09-14 2009-03-18 Virginia Tech Intellectual Properties, Inc. Production of lysosomal enzymes in plant-based expression systems
JP2820106B2 (ja) 1996-02-29 1998-11-05 日本電気株式会社 トラヒックシェーパ装置
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
CA2357004A1 (en) 1998-12-23 2000-06-29 Boyce Thompson Institute For Plant Research Expression of immunogenic hepatitis b surface antigens in transgenic plants
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6770799B2 (en) 2000-03-17 2004-08-03 Thompson Boyce Plant Res Expression of recombinant human acetylcholinesterase in transgenic plants
AU2001269923A1 (en) * 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AU2001286636A1 (en) 2000-08-25 2002-03-13 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
JP4641705B2 (ja) 2001-04-30 2011-03-02 ザイストール セラピューティクス， インコーポレイテッド 治療的タンパク質の亜細胞標的化
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
IES20011101A2 (en) * 2001-12-21 2003-06-25 Japkinstill Services Ltd A Bi-directional Messaging System
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
US7585518B2 (en) 2002-11-19 2009-09-08 Kimberly-Clark Worldwide, Inc. Products and methods for maintaining or increasing ceramide levels in skin
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
CN101027388A (zh) * 2003-06-12 2007-08-29 建新公司 具有增强活性的修饰的人酸性神经磷脂酶及其制备方法
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
JP2007514661A (ja) 2003-11-25 2007-06-07 マウント シナイ スクール オブ メディスン オブ ニューヨーク ユニバーシティー ニーマンピック病のシャペロンに基づく治療方法
DE602005021379D1 (de) 2004-10-13 2010-07-01 Protalix Ltd System und verfahren zur produktion von antikörpern in der pflanzenzellkultur
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
KR20080082984A (ko) 2005-12-15 2008-09-12 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 혈장 및 조직의 스핑고마이엘린 및 포스파티딜콜린의효소적 측정 방법
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US10265412B2 (en) 2006-02-06 2019-04-23 Ramot At Tel-Aviv University Ltd. Enzyme replacement therapy for treating lysosomal storage diseases
EP1988823B1 (en) * 2006-02-09 2018-08-15 Genzyme Corporation Slow intraventricular delivery
JP2009526526A (ja) 2006-02-13 2009-07-23 フラウンホーファー ユーエスエー， インコーポレイテッド インフルエンザ抗原、ワクチン組成物、および関連する方法
JP5302189B2 (ja) 2007-04-27 2013-10-02 長瀬産業株式会社 スフィンゴミエリナーゼ
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
EP2889043B1 (en) 2008-12-16 2019-04-10 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
EP3482767B1 (en) * 2009-08-28 2021-10-06 Icahn School of Medicine at Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
JP6175431B2 (ja) * 2011-06-20 2017-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法

Also Published As

Publication number Publication date
PT2470199T (pt) 2019-08-07
KR20230164773A (ko) 2023-12-04
JP5955219B2 (ja) 2016-07-20
IL266915A (en) 2019-07-31
IL300625A (en) 2023-04-01
SI3482767T1 (sl) 2022-03-31
JP2018076322A (ja) 2018-05-17
KR102094253B1 (ko) 2020-03-31
US10188705B2 (en) 2019-01-29
KR102608551B1 (ko) 2023-12-04
JP7395693B2 (ja) 2023-12-11
US20220305091A1 (en) 2022-09-29
MX356873B (es) 2018-06-18
DK2470199T3 (da) 2019-08-05
NL301211I1 (nl) 2022-12-28
JP2023012499A (ja) 2023-01-25
RU2020128994A (ru) 2022-03-02
BR112012004377A2 (pt) 2017-12-12
RU2569744C2 (ru) 2015-11-27
HUE057440T2 (hu) 2022-05-28
EP3998078A1 (en) 2022-05-18
US20210077593A1 (en) 2021-03-18
HUE046598T2 (hu) 2020-03-30
US20190151419A1 (en) 2019-05-23
AU2010286550B2 (en) 2016-05-19
CL2012000495A1 (es) 2014-02-07
EP2470199A4 (en) 2013-03-27
AU2016216625B2 (en) 2018-07-05
US20130078231A1 (en) 2013-03-28
IL218324B (en) 2019-05-30
NL301211I2 (nl) 2023-02-02
US8658162B2 (en) 2014-02-25
LT3482767T (lt) 2022-01-10
EP3482767B1 (en) 2021-10-06
DK3482767T3 (da) 2021-12-20
EP3482767A1 (en) 2019-05-15
RU2015145255A3 (pt) 2019-08-12
US9655954B2 (en) 2017-05-23
US20160120957A1 (en) 2016-05-05
FR22C1062I1 (fr) 2023-02-03
AU2024201085A1 (en) 2024-03-07
JP2013502933A (ja) 2013-01-31
JP2016153408A (ja) 2016-08-25
JP2022003065A (ja) 2022-01-11
KR20220104271A (ko) 2022-07-26
AU2016216625A1 (en) 2016-09-15
LT2470199T (lt) 2019-10-10
US20110052559A1 (en) 2011-03-03
JP6952810B2 (ja) 2021-10-20
IL218324A0 (en) 2012-04-30
US20140335070A1 (en) 2014-11-13
ES2738859T3 (es) 2020-01-27
WO2011025996A3 (en) 2012-03-15
RU2012111823A (ru) 2013-10-10
HUS2200050I1 (hu) 2022-12-28
SI2470199T1 (sl) 2019-11-29
KR20200034828A (ko) 2020-03-31
JP6251307B2 (ja) 2017-12-20
CN106047835A (zh) 2016-10-26
US20130078230A1 (en) 2013-03-28
IL266915B2 (en) 2023-07-01
JP2024026214A (ja) 2024-02-28
IL266915B1 (en) 2023-03-01
RU2015145255A (ru) 2019-01-11
PL2470199T3 (pl) 2019-11-29
FR22C1062I2 (fr) 2023-12-29
KR20210107153A (ko) 2021-08-31
TR201911293T4 (tr) 2019-08-21
KR20120081077A (ko) 2012-07-18
US20180055916A1 (en) 2018-03-01
AU2010286550A1 (en) 2012-03-15
AU2018204156B2 (en) 2020-07-16
WO2011025996A2 (en) 2011-03-03
AU2018204156A1 (en) 2018-06-28
EP2470199A2 (en) 2012-07-04
CA2773133A1 (en) 2011-03-03
WO2011025996A9 (en) 2011-08-25
AU2020256322B2 (en) 2024-02-29
RU2731616C2 (ru) 2020-09-07
CN105999238A (zh) 2016-10-12
ZA201601362B (en) 2017-05-31
US8349319B2 (en) 2013-01-08
MX2012002449A (es) 2012-03-14
JP7167281B2 (ja) 2022-11-08
KR102608546B1 (ko) 2023-12-04
ES2902229T3 (es) 2022-03-25
US9114139B2 (en) 2015-08-25
US8709408B2 (en) 2014-04-29
EP2470199B1 (en) 2019-05-22
ZA201201435B (en) 2020-05-27
HRP20191385T1 (hr) 2019-11-01
CY1122128T1 (el) 2020-11-25
AU2020256322A1 (en) 2020-11-12
JP2020090513A (ja) 2020-06-11
HRP20211992T1 (hr) 2022-04-01
PL3482767T3 (pl) 2022-02-14
CN102596232A (zh) 2012-07-18

Similar Documents

Publication Publication Date Title
HUS2200050I1 (hu) Dóziseszkalációs enzim helyettesítõ terápia savas szfingomielináz elégtelenség kezelésére
EP2308493A4 (en) ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
IL253293B (en) Desferrioxamine complexes of metals for the treatment of diseases related to the immune system
EP2166093A4 (en) PHARMACEUTICAL COMPOSITION FOR ENZYMATIC REPLACEMENT THERAPY
IL245283B (en) Use of lysosomal acid lipase to treat lysosomal acid lipase deficiency in patients
IL275350B (en) Treatment of neoplastic diseases
HK1163524A1 (zh) 胰腺腫瘤治療
SI2473172T1 (sl) Bisfosfonat sestavki in postopki za zdravljenje srčne okvare
EP2675472A4 (en) METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
EP2397157A4 (en) PROMOTER OF DIFFERENTIATION OF CEREBRAL TUMOR STEM CELLS AND THERAPEUTIC AGENT FOR USE IN CEREBRAL TUMORS
ZA201301279B (en) Preventive or therapeutic agent for fibrosis
ZA201009063B (en) Diaryl ureas for treating heart failure
IL216491A0 (en) Combination therapy for the treatment of multiple myeloma
ZA201201894B (en) Pharmaceutical combination for treating tumor
GB0909239D0 (en) Targeted gene therapy
IL218160A0 (en) Desferrioxamine-metal complexes for the treatment of immune-related disorders